Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jul 13:3:57-61.
doi: 10.2147/RRTM.S33108. eCollection 2012.

Anti-infective medicine quality: analysis of basic product quality by approval status and country of manufacture

Roger Bate  1 , Lorraine Mooney  2 , Kimberly Hess  3 , Julissa Milligan  1 , Amir Attaran  4
Affiliations
Review

Anti-infective medicine quality: analysis of basic product quality by approval status and country of manufacture

Roger Bate et al. Res Rep Trop Med. .

Abstract

Background: Some medicines for sale in developing countries are approved by a stringent regulatory authority (SRA) or the World Health Organization (WHO) prequalification program; many of these are global brands. This study ascertains whether medicines approved by SRAs or the WHO perform better in simple quality tests than those that have not been approved by either.

Methods: Over the past 4 years, 2652 essential drugs (products to treat malaria, tuberculosis, and bacterial infections) were procured by covert shoppers from eleven African cities and eight cities in a variety of mid-income nations. All samples were assessed using the Global Pharma Health Fund eV Minilab® protocol to identify whether they were substandard, degraded, or counterfeit.

Results: The failure rate among SRA-approved products was 1.01%, among WHO-approved products was 6.80%, and 13.01% among products that were not approved by either. African cities had a greater proportion of SRA- or WHO-approved products (31.50%) than Indian cities (26.57%), but they also experienced a higher failure rate (14.21%) than Indian cities (7.83%). The remainder of cities tested had both the highest proportion of approved products at 34.46% and the lowest failure rate at 2.70%. Products made in Africa had the highest failure rate at 25.77%, followed by Chinese products at 15.74%, Indian products at 3.70%, and European/US products, which failed least often, at 1.70%. Most worrying is that 17.65% of Chinese products approved by the WHO failed.

Conclusion: The results strongly indicate that approval by either an SRA or the WHO is correlated with higher medicine quality at a statistically significant level. The comparatively high failure rates among WHO-approved products suggest there may be some weakness in post-marketing surveillance of these products, especially of Chinese-made WHO-approved products. The discrepancy between the failure rate of WHO-approved products from India (2.39%) and China (17.65%) is cause for concern. It is possible that more of the failures originating in China are counterfeit products, but this cannot be ascertained without greater help from the manufacturers themselves.

Keywords: China; India; World Health Organization prequalification program; counterfeit; product approval; stringent regulatory authority.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

    1. World Health Organization (WHO) Guideline on Submission of Documentation for Prequalification of Multisource (Generic) Finished Pharmaceutical Products (FPPs) Approved by Stringent Regulatory Authorities (SRAs) Geneva: WHO; 2011. [Accessed April 26, 2012]. Document number: PQP09001/Ver.1. Available from: http://apps.who.int/prequal/info_applicants/Guidelines/PQProcGenericSRA_....
    1. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). FAQs: ICH organizational structure [web page on the Internet]; Geneva: ICH; 2012. [Accessed April 26, 2012]. Available from: http://www.ich.org/about/faqs.html.
    1. Bate R, Hess K, Mooney L. Antimalarial medicine diversion: stock-outs and other public health problems. Res Rep Trop Med. 2010;1:19–24.
    1. Ratanawijitrasin S, Wondemagegnehu E. Effective Drug Regulation: A Multicountry Study. Geneva: WHO; 2002. [Accessed April 18, 2012]. Available from: http://apps.who.int/medicinedocs/en/d/Js2300e/
    1. Hill S, Johnson K. Emerging Challenges and Opportunities in Drug Registration and Regulation in Developing Countries. London: DFID Health Systems Resource Centre; 2004. [Accessed April 18, 2012]. Available from: http://www.hlsp.org/LinkClick.aspx?fileticket=0TXMdaAk5KA%3D&tabid=1643.